The HudsonAlpha Research Seminars featured University of California-Los Angeles (UCLA) scientist Stanley Nelson, MD, on February 21. Dr. Nelson presented “Genomic technology impact on clinical care and insights for therapeutics in rare disease” for a packed auditorium.
Dr. Nelson is professor of human genetics and pathology and laboratory medicine at UCLA and co-director of the Center for Duchenne Muscular Dystrophy at UCLA. He has a longstanding interest in genomic technology and impact on clinical care and therapeutic insights. He established the Clinical Genomics Center at UCLA, which implemented clinical exome sequencing, and is principle investigator of the UCLA clinical site of the Undiagnosed Diseases Network. His talk will focus on how genomics in clinical practice is changing care, leading to novel disease insights and new therapeutics. Using relevant successes in Duchenne muscular dystrophy and spinal muscular atrophy, he will discuss two recent FDA approvals and discuss some issues in relation to drug approval for rare disease therapies.
Richard Myers, PhD, president and science director and a faculty investigator at HudsonAlpha, hosted the Wednesday seminar. The next seminar will feature Toby Bloom, PhD, of the New York Genome Center on Wednesday, March 21. For more information about HudsonAlpha Research Seminars, including an upcoming schedule, please visit hudsonalpha.org/seminars.
